Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The S-phase kinase-associated protein 2 (Skp2)-Cyclin-dependent kinase regulatory subunit 1 (Cks1) protein-protein interface is a pivotal regulatory node within the SCF^Skp2 E3 ubiquitin ligase complex (UniProt P63272, P61024). This interface is specifically required for the recruitment and polyubiquitination of the cyclin-dependent kinase inhibitor p27^Kip1, a key negative regulator of the G1/S phase transition (PubMed: 22854781). In various malignancies, including breast and prostate cancers, the overexpression of Skp2 and Cks1 facilitates the accelerated degradation of p27, driving oncogenic cell proliferation and poor clinical outcomes (PubMed: 23839240). Targeting this interface with small molecules aims to stabilize p27 levels and restore cell cycle control. Experimental inhibitors like Compound 67 and SZL-P1-41 have demonstrated the feasibility of disrupting this interaction to induce cell cycle arrest and apoptosis in cancer cells (PubMed: 22854781, 25201210). Unlike general proteasome inhibitors, targeting the Skp2-Cks1 interface offers a more selective strategy for modulating the ubiquitin-proteasome system in oncology. The structural basis of this interface involves the binding of Cks1 to the leucine-rich repeat domain of Skp2, creating a unique pocket for the phosphorylated Thr187 residue of p27 (PubMed: 16209941). Therapeutic development focuses on identifying drug-like molecules that can penetrate this shallow interface to prevent substrate binding without affecting other SCF complex functions.
Small molecule inhibition of the protein-protein interaction between Skp2 and its cofactor Cks1, or the blocking of the substrate-binding pocket formed by the Skp2-Cks1 complex, which prevents the ubiquitination and subsequent proteasomal degradation of the tumor suppressor p27^Kip1.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S-phase kinase-associated protein 2-Cyclin-dependent kinase regulatory subunit 1 protein-protein interface (Skp2-Cks1 interface).